Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tuberculosis chemotherapy today.

A K Dutt, W W Stead

    Annals of the Academy of Medicine, Singapore
    |July 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Short-course chemotherapy for tuberculosis offers effective treatment in six to nine months, improving patient compliance and controlling infection spread. Regimens are adaptable for developing countries, considering drug availability and cost constraints.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Opportunities for Training in Biomedical Informatics at Vanderbilt University.

    Yearbook of medical informatics·2016
    Same author

    Persistence of a strain of Mycobacterium tuberculosis in a prison system.

    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2004
    Same author

    Self injection of organophosphorous insecticide.

    The Journal of the Association of Physicians of India·2001
    Same author

    Variation in vulnerability to tuberculosis in America today: random, or legacies of different ancestral epidemics?

    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2001
    Same author

    Get both the medicine and the informatics right.

    Journal of the American Medical Informatics Association : JAMIA·2001
    Same author

    Recurrent tuberculosis due to exogenous reinfection.

    The New England journal of medicine·2001

    Area of Science:

    • Infectious Diseases
    • Public Health
    • Pharmacology

    Background:

    • Tuberculosis (TB) chemotherapy reduces mortality and controls infection spread.
    • Conventional TB therapy (18-24 months) faces challenges with patient non-compliance.
    • Advances in understanding drug action enable shorter, effective TB treatment regimens.

    Purpose of the Study:

    • To review effective short-course chemotherapy regimens for tuberculosis.
    • To address challenges in TB treatment, particularly in developing countries.
    • To highlight the benefits of modern short-course chemotherapy for patient adherence and treatment success.

    Main Methods:

    • Review of established and emerging bactericidal chemotherapy regimens for tuberculosis.
    • Analysis of drug combinations, durations, and administration frequencies.

    Related Experiment Videos

  • Consideration of treatment strategies for drug resistance and extrapulmonary TB.
  • Evaluation of regimen suitability for developing countries, factoring in drug availability and cost.

    • Main Results:

    • Nine-month regimens of isoniazid and rifampin are effective but not recommended in areas with high isoniazid resistance.
    • A four-drug regimen (streptomycin/ethambutol, isoniazid, rifampin, pyrazinamide) for two months followed by a two-drug phase is highly effective, even with isoniazid resistance.
    • Short-course regimens are available for developing countries, balancing efficacy with resource limitations.
    • Extrapulmonary tuberculosis treatment follows similar protocols to pulmonary TB.

    Conclusions:

    • Short-course chemotherapy (6-9 months) is a viable and effective strategy for tuberculosis treatment.
    • Regimen selection must consider local drug resistance patterns and resource availability.
    • Modern short-course chemotherapy enhances patient compliance and treatment completion rates, crucial for controlling TB globally.